Search

Search Constraints

You searched for: Author/Creator Camarda, Floriana

Search Results

1. 2022-LBA-746-ESGO Implementation of a comprehensive cancer genome profiling programme into clinical practice: an italian experience in a referral centre for gynecological cancers. (27th October 2022)

2. 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician's choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). (20th October 2022)

3. Advanced and recurrent endometrial cancer: State of the art and future perspectives. (December 2022)

4. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. Issue 3 (March 2023)

5. Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review. (December 2021)

6. MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. (November 2022)

7. Recent progress in the use of pharmacotherapy for endometrial cancer. (2nd January 2023)

9. TP003/#1533 MITO CERV3_phase II study on carboplatin-paclitaxel-pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer. (4th December 2022)

10. TP033/#1441 MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer. (4th December 2022)